Managing CDG: Building Your Child's Care Team
At a Glance
Managing Congenital Disorder of Glycosylation (CDG) requires a coordinated multidisciplinary care team led by a metabolic geneticist. Because CDG affects multiple organ systems, management focuses on supportive care, therapy, and preventing complications like blood clots and stroke-like episodes.
Managing a rare disease like CDG requires more than just one doctor; it requires a coordinated “medical home.” Because CDG can affect almost every organ, the standard of care centers on a multidisciplinary approach—a team of specialists who communicate with each other to manage your child’s unique symptoms [1][2].
Building Your Care Team
The 2019 international consensus guidelines for PMM2-CDG (the most common form) recommend that every child be evaluated across all organ systems [1]. Your team should ideally be led by a Metabolic Geneticist who acts as the “quarterback” for the other specialists:
- Neurologist: Focuses on balance, muscle tone, and monitoring for seizures or “stroke-like episodes” [3][4].
- Gastroenterologist / Nutritionist: Ensures your child is gaining weight and monitors for liver issues [5].
- Hematologist: Monitors the proteins that help blood clot, as CDG often lowers these levels [6].
- Cardiologist: Performs regular EKGs and ultrasounds (echocardiograms) to check for fluid around the heart or heart muscle weakness [7][8].
- Endocrinologist: Monitors growth hormones, blood sugar (hypoglycemia), and thyroid function [9][10].
- Therapists (PT/OT/SLP): Provide the “daily medicine” of rehabilitation to help with motor skills and communication [11].
Managing Common Complications
Since there is currently no curative treatment for most types of CDG, management is supportive and preventive [12][13].
Blood Clotting (Coagulation)
Many children with CDG have low levels of natural “blood thinners” like Antithrombin III, Protein C, and Protein S [6].
- The Risk: This can lead to an increased risk of both bleeding (16% frequency) and dangerous blood clots (10% frequency) [6].
- Management: Your team will likely check these levels regularly, especially before any surgery or during a major illness.
Stroke-like Episodes (SLE)
Unique to certain types of CDG (like PMM2-CDG), these events can look like a stroke but are usually triggered by a fever, infection, or minor head trauma [14].
- Emergency Protocol: Parents should have a written “rescue plan” from their doctor. This usually involves intravenous (IV) hydration at the hospital, fever management, and sometimes monitoring in a hospital setting to prevent complications [14].
Immune System
Some children with CDG, particularly infants, are more prone to infections [15][16]. Your team may recommend a specific vaccination schedule or, in some cases, consultation with an Immunologist if your child is getting sick frequently [15].
Vetting Your Specialists
When meeting a new specialist, you can use these questions to see if they are a good fit for your child’s complex needs:
- “Are you familiar with the specific multisystem risks associated with CDG, or are you willing to consult with a metabolic expert who is?”
- “How do you prefer to communicate with the other members of my child’s care team, and are you willing to update our local primary pediatrician?”
- “Can you help us establish ‘baseline’ tests for my child so we know what is ‘normal’ for them before an emergency happens?”
Learn about the long term journey in Long-Term Outlook and Surveillance.
Common questions in this guide
What type of doctor should lead a CDG care team?
What triggers stroke-like episodes in children with CDG?
Why do children with CDG need to be monitored by a hematologist?
What therapies are recommended for daily CDG management?
Get notified when new evidence is published on Congenital disorder of glycosylation.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.
Altassan R, Péanne R, Jaeken J, et al.
Journal of inherited metabolic disease 2019; (42(1)):5-28 doi:10.1002/jimd.12024.
PMID: 30740725 - 2
Multiorgan involvement and genetic spectrum of 20 Chinese patients with PMM2-CDG.
Zhang H, Zhang J, Ma W, et al.
Molecular genetics and metabolism 2025; (145(4)):109178 doi:10.1016/j.ymgme.2025.109178.
PMID: 40555085 - 3
Stroke-Like Episodes in PMM2-CDG: When the Lack of Other Evidence Is the Only Evidence.
Serrano M
Frontiers in pediatrics 2021; (9()):717864 doi:10.3389/fped.2021.717864.
PMID: 34708008 - 4
Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directions.
Muthusamy K, Perez-Ortiz JM, Ligezka AN, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2024; (26(2)):101027 doi:10.1016/j.gim.2023.101027.
PMID: 37955240 - 5
Nutritional Therapies in Congenital Disorders of Glycosylation (CDG).
Witters P, Cassiman D, Morava E
Nutrients 2017; (9(11)) doi:10.3390/nu9111222.
PMID: 29112118 - 6
Coagulation abnormalities in a prospective cohort of 50 patients with PMM2-congenital disorder of glycosylation.
De Graef D, Ligezka AN, Rezents J, et al.
Molecular genetics and metabolism 2023; (139(2)):107606 doi:10.1016/j.ymgme.2023.107606.
PMID: 37224763 - 7
Clinical severity and cardiac phenotype in phosphomannomutase 2-congenital disorders of glycosylation : Insights into genetics and management recommendations.
Holubova V, Barone R, Grunewald S, et al.
Journal of inherited metabolic disease 2025; (48(1)):e12826 doi:10.1002/jimd.12826.
PMID: 39633515 - 8
Novel Splicing Variant in the PMM2 Gene in a Patient With PMM2-CDG Syndrome Presenting With Pericardial Effusion: A Case Report.
Slaba K, Noskova H, Vesela P, et al.
Frontiers in genetics 2020; (11()):561054 doi:10.3389/fgene.2020.561054.
PMID: 33133147 - 9
Suspected Central Adrenal Insufficiency in a Patient with Phosphomannomutase 2-Congenital Disorder of Glycosylation.
Ødum SF, Grønborg SW, Main KM, Klose M
JCEM case reports 2025; (3(11)):luaf237 doi:10.1210/jcemcr/luaf237.
PMID: 41080975 - 10
Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screened for adrenal insufficiency?
Čechová A, Honzík T, Edmondson AC, et al.
Molecular genetics and metabolism 2021; (133(4)):397-399 doi:10.1016/j.ymgme.2021.06.003.
PMID: 34140212 - 11
Experiences of parents with children with congenital disorders of glycosylation: What can we learn from them?
Cardão C, Barros L, Francisco R, et al.
Disability and health journal 2021; (14(3)):101065 doi:10.1016/j.dhjo.2021.101065.
PMID: 33531289 - 12
[Advances in the diagnosis and treatment of phosphomannomutase 2 deficiency].
Zhou SY
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2023; (25(2)):223-228 doi:10.7499/j.issn.1008-8830.2209049.
PMID: 36854702 - 13
New and potential strategies for the treatment of PMM2-CDG.
Gámez A, Serrano M, Gallego D, et al.
Biochimica et biophysica acta. General subjects 2020; (1864(11)):129686 doi:10.1016/j.bbagen.2020.129686.
PMID: 32712172 - 14
Association between acute complications in PMM2-CDG patients and haemostasis anomalies: Data from a multicentric study and suggestions for acute management.
Wicker C, Roux CJ, Goujon L, et al.
Molecular genetics and metabolism 2023; (140(3)):107674 doi:10.1016/j.ymgme.2023.107674.
PMID: 37542768 - 15
Revisiting the immunopathology of congenital disorders of glycosylation: an updated review.
Pascoal C, Francisco R, Mexia P, et al.
Frontiers in immunology 2024; (15()):1350101 doi:10.3389/fimmu.2024.1350101.
PMID: 38550576 - 16
Compound heterozygous variants in MOGS inducing congenital disorders of glycosylation (CDG) IIb.
Li M, Xu Y, Wang Y, et al.
Journal of human genetics 2019; (64(3)):265-268 doi:10.1038/s10038-018-0552-6.
PMID: 30587846
This page provides educational information about building a care team and managing Congenital Disorder of Glycosylation (CDG). It does not replace professional medical advice or personalized emergency protocols from your child's medical specialists.